EP0551182A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
Assignee: Wyeth LLC
•
Filing: 1993-01-06
•
Granted: —
•
Expires: 2013-01-06
Abstract
Abstract This invention provides a method of preventing or treating hyperpoliferative vascular disease in a mammal by administering an antiproliferative effective amount of rapamycin alone or in combination with mycophenolic acid.
Inventors
- 👤 Randall Ellis Morris
- 👤 Clare Robert Gregory
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 01:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/4353; A61K31/436; A61K31/70; A61K31/335; A61K31/357; A61K31/36; A61K45/00; A61K45/06; A61P; A61P43/00; A61P9/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
21 words
Use of rapamycin in the manufacture of a medicament for use in preventing or treating hyperproliferative vascular disease in a mammal.
Claim 2
Dependent Claim
29 words
Use as claimed in Claim 1 in which the medicament is adapted for administration orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via a vascular stent impregnated with rapamycin.
Claim 3
Dependent Claim
22 words
Use as claimed in Claim 1 or Claim 2 in which the medicament comprises mycophenolic acid for simultaneous separate or sequential administration.
Claim 4
Dependent Claim
23 words
Product containing rapamycin and mycophenolic acid as a combined preparation for simultaneous, separate or sequential use in preventing or treating hyperproliferative vascular disease.
Claim 5
Dependent Claim
30 words
A use or product according to any one of claims 1 to 4 wherein the hyperproliferative vascular disease is selected from intimal smooth muscle cell hyperplasia, restenosis and vascular occlusion.
Claim 6
Dependent Claim
32 words
A use or product according to any one of Claims 1 to 4 wherein the rapamycin is administered concurrent with and/or subsequent to said mammal undergoing a percutaneous transluminal coronary angioplasty procedure.
Claim 7
Dependent Claim
20 words
A use or product according to any one of Claims 1 to 4 wherein the hyperproliferative vascular disease is restenosis.
Claim 8
Dependent Claim
33 words
A use or product according to any one of Claims 1 to 4 wherein the rapamycin is administered concurrent with and/or subsequent to said mammal sustaining a biologically or mechanically mediated vascular injury.
Claim 9
Dependent Claim
12 words
A pharmaceutical composition comprising rapamycin, mycophenolic acid and a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US5078999A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.